Ernexa Therapeutics Inc. (ERNA) Revenue History
Annual and quarterly revenue from 2015 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ERNA Revenue Growth
ERNA Revenue Analysis (2015–2025)
As of May 8, 2026, Ernexa Therapeutics Inc. (ERNA) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, ERNA's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $24.5 million in 2015.
When compared to Healthcare sector peers including FATE (-51.2% YoY), CRSP (-88.9% YoY), and BEAM (+108.0% YoY), ERNA has underperformed the peer group in terms of revenue growth. Compare ERNA vs FATE →
ERNA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ERNACurrent | $0 | -100.0% | - | - | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% |
ERNA Historical Revenue Data (2015–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $-263,000 | - | $-9,319,000 | - |
| 2024 | $582K | +755.9% | $486K | 83.5% | $-15,674,000 | -2693.1% |
| 2023 | $68K | - | $-168,000 | -247.1% | $-21,135,000 | -31080.9% |
| 2022 | $0 | - | $0 | - | $-33,217,000 | - |
| 2021 | $0 | - | $0 | - | $-113,732,000 | - |
| 2020 | $0 | -100.0% | $-98,000 | - | $-7,248,000 | - |
| 2019 | $19.8M | -15.1% | $12.0M | 60.4% | $-1,212,000 | -6.1% |
| 2018 | $23.3M | +9.7% | $14.9M | 64.1% | $464K | 2.0% |
| 2017 | $21.3M | -4.7% | $14.2M | 66.7% | $-1,402,000 | -6.6% |
| 2016 | $22.3M | -9.0% | $14.2M | 63.6% | $-2,278,000 | -10.2% |
See ERNA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ERNA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ERNA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonERNA — Frequently Asked Questions
Quick answers to the most common questions about buying ERNA stock.
Is ERNA's revenue growth accelerating or slowing?
ERNA revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $0.00. This reverses the prior growth trend.
What is ERNA's long-term revenue growth rate?
Ernexa Therapeutics Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is ERNA's revenue distributed by segment?
ERNA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2025 are available for download. Segment mix reveals concentration and diversification trends.